Shionogi Valuation Multiples

Shionogi Overview

About Shionogi

Shionogi & Co Ltd is a specialty and generic drug manufacturing company. The company focuses on the manufacturing and distribution of pharmaceuticals, diagnostic reagents, and medical devices. The company engages in manufacturing, formulation, packaging, and analysis as part of its commercialization research that spans late-stage drug discovery through commercial production. It provides products and services in Japan, Europe, North America, and other regions.

Founded

1919

HQ

Employees

5.5K

Website

shionogi.com

Sectors

BiopharmaceuticalsBioTechHealthTech

Financials (LTM)

Revenue: $3B

EBITDA: $1B

EV

$14B

Valuation Multiples

Multiples.vc

Start free trial

Shionogi Financials

Shionogi reported last 12-month revenue of $3B and EBITDA of $1B.

In the same LTM period, Shionogi generated $3B in gross profit, $1B in EBITDA, and $1B in net income.

Shionogi P&L

In the most recent fiscal year, Shionogi reported revenue of $3B and EBITDA of $1B.

Shionogi expects next 12-month revenue of XXX and NTM EBITDA of XXX

Shionogi Stock Performance

Shionogi has current market cap of $17B, and enterprise value of $14B.

Shionogi's stock price is $20.30.

Shionogi Valuation Multiples

Shionogi trades at 4.2x EV/Revenue multiple, and 9.9x EV/EBITDA.

Shionogi Financial Valuation Multiples

As of April 19, 2026, Shionogi has market cap of $17B and EV of $14B.

Equity research analysts estimate Shionogi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Shionogi has a P/E ratio of 13.9x.

Shionogi Margins & Growth Rates

Shionogi's revenue in the last 12 month grew by 34%.

Shionogi's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.

Shionogi's rule of 40 is 77% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Shionogi's rule of X is 124% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Shionogi Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Shionogi M&A Activity

Shionogi acquired XXX companies to date.

Last acquisition by Shionogi was on XXXXXXXX, XXXXX. Shionogi acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Shionogi Investment Activity

Shionogi invested in XXX companies to date.

Shionogi made its latest investment on XXXXXXXX, XXXXX. Shionogi invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).